Meabco A/S

2 articles with Meabco A/S

• Meabco Awarded a $5.9 Million US Government Contract to Advance its BP-C2 Compound as a Medical Countermeasure for Cutaneous Radiation Injuries

  6/9/2020

  Award from the National Institute of Allergy and Infectious Diseases (NIAID) Radiation and Nuclear Countermeasures Program

• Meabco A/S's BP-Cx-1 Widens The Number Of First Line Cystostatic Agents

  12/14/2006